At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Dovitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Dovitinib and Pilot Study of Fibroblast Growth Factor Receptor Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Previously Treated With Anti-Vascular Endothelial Growth Factor Therapy
In Brief
A Phase 2 clinical trial evaluating Dovitinib for Non-Small Cell Lung Cancer and Colorectal Cancer. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to find out if dovitinib is an effective treatment for patients with advanced lung cancer or advanced colorectal cancer (CRC) who have progressed on anti-vascular endothelial growth factor (VEGF) treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer, Colorectal Cancer
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartFeb 2013
Primary CompletionJan 2016
Study CompletionJun 2016
TodayJul 2026
First PostedAug 31, 2012
Enrollment StartFeb 1, 2013
Primary CompletionJan 1, 2016
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.8 years ago
Interventions
Dovitinibdrug